Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma

Author： Ribas Christian Colleoni Gisele Almeida Manuella Duch Cibele Repele Ohashi Cláudio Segreto Roberto Silva Maria Regina

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.43, Iss.2, 2004-03, pp. : 215-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

By Srkalovic Gordan Elson Paul Trebisky Beth Karam Mary Hussein Mohamad

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 219-226

Humana Press, Inc

Access to resources Recommend Favorite

Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma

By Chiou Tzeon-Jye Wang Teng-Hsu Chao Tsu-Yi Lin Sheng-Fung Tang Jih-Luh Chen Tsai-Yun Chang Ming-Chih Hsueh Erh-Jung Chen Po-Min

Cancer Investigation, Vol. 25, Iss. 3, 2007-04 ,pp. : 140-147

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide in multiple myeloma: past, present and future

By Harousseau Jean-Luc

Future Oncology, Vol. 2, Iss. 5, 2006-10 ,pp. : 577-589

Future Medicine

Access to resources Recommend Favorite

Treatment Approaches for Relapsing and Refractory Multiple Myeloma

By Bladé Joan Esteve Jordi

Acta Oncologica, Vol. 39, Iss. 7, 2000-11 ,pp. : 843-847

Informa Healthcare

Access to resources Recommend Favorite

Advances in treatment for relapses and refractory multiple myeloma

By Richards Tiffany Weber Donna

Medical Oncology, Vol. 27, Iss. 1, 2010-06 ,pp. : 25-42

Humana Press, Inc

Access to resources Recommend Favorite